Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 24
1991 73
1992 138
1993 227
1994 228
1995 311
1996 338
1997 348
1998 375
1999 383
2000 404
2001 437
2002 507
2003 460
2004 427
2005 438
2006 399
2007 372
2008 370
2009 383
2010 394
2011 444
2012 435
2013 429
2014 418
2015 410
2016 315
2017 309
2018 318
2019 333
2020 312
2021 345
2022 297
2023 273
2024 265
2025 39

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,039 results

Results by year

Filters applied: . Clear all
Page 1
Losartan: Comprehensive Profile.
Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA. Al-Majed AR, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:159-94. doi: 10.1016/bs.podrm.2015.02.003. Epub 2015 Apr 9. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051686 Review.
Losartan (Cozaar) is an angiotensin II receptor antagonist with antihypertensive activity. ...Physical characteristics including: ionization constant, solubility, X-ray powder diffraction pattern, thermal methods of analysis, UV spectrum, IR spectrum, mass spectrum with fr
Losartan (Cozaar) is an angiotensin II receptor antagonist with antihypertensive activity. ...Physical characteristics including: ion
Clinical pharmacokinetics of losartan.
Sica DA, Gehr TW, Ghosh S. Sica DA, et al. Clin Pharmacokinet. 2005;44(8):797-814. doi: 10.2165/00003088-200544080-00003. Clin Pharmacokinet. 2005. PMID: 16029066 Review.
Losartan is the first orally available angiotensin-receptor antagonist without agonist properties. ...Losartan, or its E 3174 metabolite, is not removed during haemodialysis. The major metabolic pathway for losartan is by the cytochrome P450 (CYP) 3A4, 2C9 an
Losartan is the first orally available angiotensin-receptor antagonist without agonist properties. ...Losartan, or its E 3174
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.
Regan DP, Chow L, Das S, Haines L, Palmer E, Kurihara JN, Coy JW, Mathias A, Thamm DH, Gustafson DL, Dow SW. Regan DP, et al. Clin Cancer Res. 2022 Feb 15;28(4):662-676. doi: 10.1158/1078-0432.CCR-21-2105. Clin Cancer Res. 2022. PMID: 34580111 Free PMC article.
Here we leverage dogs with spontaneous OS to determine losartan's safety and pharmacokinetics associated with monocyte pharmacodynamic endpoints, and assess its antitumor activity, in combination with the kinase inhibitor toceranib. ...RESULTS: Human and canine OS c …
Here we leverage dogs with spontaneous OS to determine losartan's safety and pharmacokinetics associated with monocyte pharmac …
[Losartan].
Quetglas EG, Sádaba B, Escolar M, Honorato J. Quetglas EG, et al. Rev Med Univ Navarra. 1997 Jul-Sep;41(3):193-7. Rev Med Univ Navarra. 1997. PMID: 10420926 Review. Spanish. No abstract available.
Losartan ameliorates renal fibrosis by inhibiting tumor necrosis factor signal pathway.
Wang H, Liu J, Fang F, Gao L, Zhao C, Wang Z, Zhong Y, Wang X. Wang H, et al. Nefrologia (Engl Ed). 2024 Mar-Apr;44(2):139-149. doi: 10.1016/j.nefroe.2024.04.001. Nefrologia (Engl Ed). 2024. PMID: 38697694 Free article. Review.
Losartan is widely used in the treatment of chronic kidney disease (CKD) and has achieved good clinical efficacy, but its exact mechanism is not clear. ...These data suggest that losartan may ameliorate renal fibrosis through modulating the TNF pathway....
Losartan is widely used in the treatment of chronic kidney disease (CKD) and has achieved good clinical efficacy, but its exact mecha
Losartan Interactions with 2-Hydroxypropyl-beta-CD.
Palli V, Leonis G, Zoupanou N, Georgiou N, Chountoulesi M, Naziris N, Tzeli D, Demetzos C, Valsami G, Marousis KD, Spyroulias GA, Mavromoustakos T. Palli V, et al. Molecules. 2022 Apr 8;27(8):2421. doi: 10.3390/molecules27082421. Molecules. 2022. PMID: 35458617 Free PMC article.
Losartan potassium salt (LSR) is a well-known antihypertensive drug with proven beneficial effects on human health. ...
Losartan potassium salt (LSR) is a well-known antihypertensive drug with proven beneficial effects on human health. ...
Losartan-induced hepatic injury.
Tabak F, Mert A, Ozaras R, Biyikli M, Ozturk R, Ozbay G, Senturk H, Aktuglu Y. Tabak F, et al. J Clin Gastroenterol. 2002 May-Jun;34(5):585-6. doi: 10.1097/00004836-200205000-00022. J Clin Gastroenterol. 2002. PMID: 11960076 Review.
Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug has demonstrated that it is safe. Losartan-induced hepatic toxicity is extremely rare. We report a case of severe hepatic toxicity a
Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug
Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-beta/Smad.
Zou J, Zhou X, Ma Y, Yu R. Zou J, et al. Biomed Pharmacother. 2022 May;149:112931. doi: 10.1016/j.biopha.2022.112931. Epub 2022 Apr 7. Biomed Pharmacother. 2022. PMID: 36068784 Free article.
In this study, we investigated the effects of losartan on Unilateral Ureteral Obstruction (UUO) model mice by studying the changes in the TGF-beta/Smad and metabolomics. Male C57BL/6 J mice were intervened with the UUO model and given losartan (10, 20, 30 mg/kg/d) f …
In this study, we investigated the effects of losartan on Unilateral Ureteral Obstruction (UUO) model mice by studying the changes in …
Losartan in diabetic nephropathy.
Perico N, Ruggenenti P, Remuzzi G. Perico N, et al. Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. doi: 10.1586/14779072.2.4.473. Expert Rev Cardiovasc Ther. 2004. PMID: 15225108 Review.
Losartan also lowered albumin excretion rate in microalbuminuric patients with Type 2 diabetes mellitus. Moreover, the large multicenter Reduction of End points in Noninsulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) trial has
Losartan also lowered albumin excretion rate in microalbuminuric patients with Type 2 diabetes mellitus. Moreover, the large multicen
11,039 results
You have reached the last available page of results. Please see the User Guide for more information.